Thus, the rate-limiting step for the
release of active IL-1β is the synthesis of the IL-1β precursor. In general, the release of active IL-1β from blood monocytes is tightly controlled with less than 20% of the total synthetic IL-1β precursor being processed and released. Although the release of active IL-1β from the blood monocytes of healthy subjects takes place over several hours 24, the process can be accelerated by the exogenous addition of ATP 19, which triggers the P2X7 purinergic receptor 26. In tissue macrophages, caspase-1 is not constitutively active 24. Extracellular ATP is required to activate the P2X7 receptor, which opens the potassium channel. Simultaneously, intracellular potassium levels fall, caspase-1 selleck products is activated, the IL-1β precursor is cleaved and secretion takes place 26. Thus, in ischemic diseases where there is cell death, release of ATP contributes to caspase-1 activation. A similar process may Tanespimycin take place in the inflammatory process of gouty arthritis. In this disease, the synovial
macrophage is induced to synthesize the IL-1β precursor following exposure to uric acid crystals in combination with free fatty acids 27. In the presence of large numbers of neutrophils, crystal-induced cell death causes the release of ATP and triggering of the P2X7 receptor. In addition, there may be a hypoxic component to the production of IL-1β in gout since the disease characteristically occurs in the most distal joints. Most human disease is sterile
and, in many cases, the release of cell contents upon necrotic death releases the IL-1α precursor. The IL-1α precursor is MycoClean Mycoplasma Removal Kit fully active and does not require caspase-1 processing. Here the concept of auto-inflammation may find its fundamental mechanism, as auto-inflammation needs auto-stimulants. One auto-stimulant is IL-1 itself as IL-1 induces itself 28. The clinical evidence behind this concept can be found in treating patients with the classic auto-inflammatory diseases such as CAPS. For example, the elevated levels of caspase-1 mRNA as well as that of IL-1β in the blood monocytes from the CINCA syndrome patients decreases dramatically with anakinra treatment but rapidly returns with cessation of anakinra 23. In addition, a single administration of an anti-IL-1β mAb results in prolonged resolution of disease activity after the antibody is cleared from the circulation 29. Similar observations have been made in patients treated with a single dose of canakinumab for gout 30. In those studies of IL-1-induced IL-1, IL-1α was used to stimulate gene expression and release of active IL-1β since the IL-1α precursor is constitutively present in all mesenchymal cells. Furthermore, the IL-1α precursor, which unlike the IL-1β precursor, binds to the IL-1 receptor and is active. Not unexpectedly, IL-1α is also the cytokine that has been consistently implicated as causing sterile inflammation due to cell death 31, 32.